Previous Page Next Page
Section Table of Contents
Site Table of Contents
Medical Pharmacology Chapter 13:  Opioid Pharmacology Lecture, slide 4

press above to begin the lecture

 

 

Table of Contents: Opioids

  • Nomenclature

  • Opioids Definition

  • Source

  • Classification/Chemistry

    • Opioid Classification

    • Chemical Substitution

  • Endogenous Opioid Peptides

  • Pharmacokinetics

    • Absorption

    • Distribution

    • Metabolism

    • Excretion

  • Pharmacodynamics

    • Mechanism of Action

    • Receptor Binding

    • Receptor Types

    • General Opioid Receptor Properties

    • Opioid Receptor Subtypes: Table

    • Cellular Actions

      • G-Protein Links

      • Two well-defined Actions

      • Spinal Cord Sites of Action

        • Presynaptic Sites

    • Opioid Receptor Distribution

  • Systemic Opioid Administration

  • Tolerance and Physical Dependence

  • Opioid Effects: Degree of Tolerance Developed

Organ Systems

  • CNS

    • Analgesia

      • Spinal Cord

      • Supraspinal Sites of Action

      • Clinical Implications

    • Euphoria

    • Sedation

    •  Respiratory Depression

    • Cough Supression

    • Miosis

      • Clinical Implications

    • Truncal Rigidity

    • Nausea and Vomiting

  • Cardiovascular Effects

  • Gastrointestinal Effects

    • Constipation

  • Biliary Tract

  • Genitourinary Tract

  • Uterus

  • Neuroendocrine

  • Pentazocine  (Talwain)(and other)-- agonist-antagonists

  • Opioid Analgesics: Efficacy; Oral/Parenteral Potency Ratio

  • Summary of Opioid Analgesic Toxic Effects

Clinical Use: Opioid Analgesics

  • Analgesia

    • Obstetrical Labor

    • Renal/Biliary Colic

    • Acute Pulmonary Edema

    • Cough

    • Diarrhea

  • Opioids and Anesthesia

    • Anesthetic Premedication

    • Intraoperative Use-general

    • Intraoperative Use-regional

    • Other routes of Administration

  • Toxicity and Side Effects

    • Tolerance

    • Cross-Tolerance

    • Physiologic Dependence

    • Antagonist-Precipitated Withdrawal

    • Psychological Dependence

    • Prescribing Principles and Guidelines

    • Management/Treatment of Overdosage

    • Contraindications/Therapeutic Cautions

      • Pregnancy

      • Impaired Lung Function

      • Impaired Liver/Kidney Function

      • Endocrine Disorders

Specific Drugs

  • Strong Agonists

    • Phenanthrenes

      • Morphine

      • Hydromorphone

      • Oxymorphone (Numorphan)

    • Phenylheptylamines

      • Methadone (Dolophine)

        • pharmacodynamics

      • Levomethadyl acetate

    • Phenylpiperidines

      • Meperidine (Demerol)

      • Fentanyl Group

        • Fentanyl (Sublimaze)

        • Sufentanil  (Sufenta)

        • Alfentanil (Alfenta)

        • Remifentanil (Ultiva)

    • Morphinans: -- Levorphanol  (Levo-dromoran)

  • Mild/Moderate Agonists

    • Codeine, oxycodone (Roxicodone), dihydrocodeine, hydrocodone

    • Propoxyphene(Darvon)

    • Diphenoxylate (Lomotil)

    • Loperamide(Imodium)

  • Mixed Agonist-Antagonists & Partial Agonists

    • Nalbuphene

    • Buprenorphine (Buprenex)

    • Butorphanol

    • Pentazocine

    • Dezocine

  • Miscellaneous

    • Tramadol

  • Antitussives

  • Opioid Antagonists-Naloxone, Naltrexone, Nalmefene

    • Pharmacodynamics

    • Clinical Use

 

Organ System Effects

 

  • Cardiovascular Effects:

    • Usually minimal effects (some bradycardia)

    • BP -- in the absence of stress, well maintained;

    • With stress hypotension may occur

      • Hypotensive reaction -- mechanism

        • Peripheral arterial dilation

        • Venous dilation

        • May be due to central vasomotor effects and histamine release

      •  Reduced blood volume:

        • Increased susceptibility to opioid hypotensive effects

    • With respiratory depression (secondary to opioid administration), PCO2 increases and causes:

      1. Cerebral vasodilation (decrease in cerebral vascular resistance)

      2. Increase in cerebral blood flow

      3. Increase in intracranial pressure

 

  • Gastrointestinal Opioid Effects:

    • Constipation:

      • Mechanism: local enteric mechanisms and CNS effects

      • Stomach:

        • Motility {rhythmic contraction/relaxation} decreases

        • Tone {constant muscle contraction level} increases

        • Gastric acid (HCl) decreases

      • Small Intestinal Effects:

        • Tone: increases; with spasm

        • Nonpropulsive contractile amplitudes decreases

      • Large Intestinal Effects

        • Propulsive peristaltic waves are diminished

        • Tone increased

        • These effects:

          1. Delay fecal passage (constipating)

          2. Promote water reabsorption (constipating)

        • Opioid pharmacological actions in the large intestine are the basis for opioid use in management of diarrhea

 

  • Biliary tract:

    • Opioids: promote biliary smooth muscle constriction possibly resulting in biliary colic

    •  Sphincter of Oddi may constrict:

      • Biliary and pancreatic secretion reflux

      • Elevated plasma lipase/amylase

 

  • Genitourinary tract:

    • Renal Function: depressed

      • Decreased renal plasma flow

      • Bladder and ureteral tone: increased

        • Urinary retention (particularly in postoperative patients)

        • Increased opioid-induced ureteral tone may worsen ureteral colic due to renal calculus

    • Uterus:

      • Prolong labor

 

  • Neuroendocrine:

    • Opioid analgesics promote release of:

      1. Antidiuretic hormone

      2. Prolactin

      3. Somatotropin

    • Opioid analgesics inhibit released of:

      • Luteinizing hormone which is probably a hypothalamic effect

 

 

  • Other Effects:

    • Flushing, sweating, itching: central effects & histamine early

    • Opioid affecting the immune system by influencing:

      1. Chemotaxis

      2. Antibody production

Pentazocine (and other)-- agonist-antagonists:

  • Common effect: sedation + analgesia-- therapeutic doses

  • Sweating, dizziness, nausea -- common at higher doses; significant respiratory depression less likely than with pure opioid agonists

    • Respiratory depression: reversible by naloxone; agonist antagonists (nalorphine) less likely to be effective in reversing respiratory depression

  • Psychotomimetic effects: agonist-antagonists

    • Nightmares

    • Anxiety

    • Hallucinations

Opioid Analgesics: Efficacy; Oral/Parenteral Potency Ratio

Generic name

Trade name

Oral/ Parenteral Potency

Maximum Efficacy

Morphine

generic

low

high

Hydromorphone

Dilaudid

low

high

Oxymorphone

Numorphan

low

high

Methadone

Dolophine

high

high

Meperidine

Demerol

medium

high

Fentanyl

Sublimaze

parenteral only

high

Sufentanil

Sufenta

parenteral only

high

Alfentanil

Alfenta

parenteral only

high

Levorphanol

Levo-Dromoran

high

high

Codeine

generic

high

medium

Oxycodone

Percodan

medium

medium

Dhydrocodeine

Drocode

medium

medium

Propoxyphene

Darvon

oral only

low

Pentazocine

Talwin

medium

low

Nnalbuphine

Nubain

parenteral only

low

Buprenorphine

Buprenex

parenteral only

low

adapted from Table 31-2: Way, W.L., Fields, H.L. and Way, E. L. Opioid Analgesics and Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p. 501; selection of an appropriate analgesic will depend on the severity and type of pain.

 

Summary of Opioid Analgesic Toxic Effects

  • Dysphoria --behavioral restlessness; hyperactivity

  • Respiratory depression

    • All opioid analgesics: significant respiratory depression (inhibiting brain stem respiratory centers)

    • Characterized by: reduced response to carbon dioxide challenge

    • Respiratory depression:

      • Dose-related

      • Influenced by extent of sensory input

      • Opioid induced --slight respiratory depression: tolerated in patients with no prior respiratory difficulty

      • Opioid induced -- slight respiratory depression: poorly or not tolerated in patients with:

        • Asthma

        • Chronic obstructive pulmonary disease (COPD)

        • Cor pulmonale (right ventricular hypertrophy secondary to pulmonary pathology or pulmonary vascular pathology)

        • Increased intracranial pressure

  • Nausea and vomiting

  • Increased intracranial pressure

    •  With respiratory depression (secondary to opioid administration), PCO2 increases and is associated with:

      1. Cerebral vasodilation (decrease in cerebral vascular resistance)

      2. Increase in cerebral blood flow

      3. Increase in intracranial pressure

  • Hypotensive states -- worsened by preexisting hypovolemia or by other medications given concurrently (e.g. nitroglycerin in acute management of myocardial infarction)

  • Constipation

  • Urinary retention

  • Urticaria, itching

adapted from Table 31-5: Way, W.L., Fields, H.L. and Way, E. L. Opioid Analgesics and Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange

 

 

 
 
 
Previous Page Next Page
Section Table of Contents
Site Table of Contents